Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for ambrisentan from Actavis Pharma, Inc., updating the drug's labeling/approved uses under ANDA…
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Sigmapharm Laboratories, LLC)
FDA approved a supplemental application for ambrisentan by Sigmapharm Laboratories to market a generic version of the drug.
-
FDA approval · 2024-08-19FDA Approved: AMBRISENTAN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Ambrisentan from Aurobindo Pharma Limited, enabling the generic form of the drug to be marke…
-
CLINICAL_TRIALS trial_result · 2024-08-19Clinical Trial Update: Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
This is a completed non-interventional postauthorization safety study evaluating Ventavis (iloprost) for pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Subcutaneous Elafin in Healthy Subjects [Phase 1]
Phase 1 trial evaluating subcutaneous elafin in healthy subjects has completed, focusing on safety and pharmacokinetics.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg [Phase 1]
Phase 1 trial evaluating a fixed-dose combination tablet of macitentan and tadalafil (10 mg/40 mg) branded as PrOpsynvi for pulmonary arteri…
-
CLINICAL_TRIALS withdrawal · 2024-08-14Clinical Trial Update: Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension [NA]
The pilot randomized trial of ambulatory exercise in pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS research · 2024-08-13Clinical Trial Update: Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension
Clinical trial update for a completed study evaluating the role of Epstein-Barr virus in patients with pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension [Phase 2]
Phase 2 clinical trial evaluating repurposing a histamine antagonist for pulmonary arterial hypertension and associated right heart failure;…
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
This is a prospective non-interventional observational study to observe long-term treatment and outcomes in patients with pulmonary arterial…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil [Phase 3]
Phase 3 results update on the safety and pharmacology of dry powder inhaled treprostinil for pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: Medication Reconciliation in Pulmonary Hypertension
A clinical trial evaluating medication reconciliation in pulmonary hypertension has completed, covering conditions such as pulmonary hyperte…
-
FDA approval · 2024-07-08FDA Approved: SILDENAFIL — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for sildenafil citrate (ANI Pharmaceuticals, Inc.) under an approved ANDA.
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets [Phase 1]
This Phase 1 bioequivalence study compares Bosentan 32 mg dispersible tablets to Tracleer 32 mg tablets in patients with Pulmonary Arterial …
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Spironolactone Therapy in Chronic Stable Right HF Trial [Phase 4]
A Phase 4 clinical trial assessing spironolactone therapy in patients with chronic stable right heart failure, including those with pulmonar…
-
EMA approval · 2024-06-28Positive CHMP opinion on first-in-class medicine to treat pulmonary arterial hypertension
The European Medicines Agency's CHMP issued a positive opinion for Winrevair, a first-in-class medicine for pulmonary arterial hypertension,…
-
CLINICAL_TRIALS research · 2024-06-26Clinical Trial Update: Taiwan Interstitial Lung Disease Multi-center Investigation and Registry
A multi-center registry study in Taiwan focusing on interstitial lung disease and related comorbidities is currently recruiting.
-
CLINICAL_TRIALS research · 2024-06-25Clinical Trial Update: Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension [NA]
Clinical trial update on cardiac function and exercise capacity in pulmonary arterial hypertension; the study status is completed.
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia [Phase 2]
Phase 2 clinical trial update evaluating whether supplemental oxygen improves six-minute walk distance in hypoxemic patients with pulmonary …
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Effects of UE Aerobic Exercise on Exercise Capacity and PA in Patients With Pulmonary Arterial Hypertension. [NA]
This clinical trial evaluated whether upper-extremity aerobic exercise improves exercise capacity and physical activity in patients with pul…
-
FDA approval · 2024-06-12FDA Approved: EPOPROSTENOL — Original Application (Mylan Institutional LLC)
FDA approved the generic epoprostenol injection from Mylan Institutional LLC under an Original Application; epoprostenol is used to treat pu…
-
CLINICAL_TRIALS research · 2024-06-12Clinical Trial Update: Implementing the Wuqinxi on Patients With Pulmonary Arterial Hypertension [NA]
A clinical trial update describing the implementation of Wuqinxi, a traditional exercise, for patients with pulmonary arterial hypertension;…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
This clinical trial update discusses the frequency of bleeding events in patients with pulmonary arterial hypertension who are receiving ant…
-
FDA label_change · 2024-05-30FDA Approved: BOSENTAN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Bosentan from Zydus Pharmaceuticals USA Inc. The update aligns the generic's labeling with the b…
-
CLINICAL_TRIALS research · 2024-05-28Clinical Trial Update: Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension [NA]
A Potts-shunt procedure is being studied for pediatric patients with severe pulmonary arterial hypertension, with recruitment currently ongo…